European Journal of Vascular & Endovascular Surgery
Volume 40, Issue 1 , Pages 9-16 , July 2010

Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease: Data from the REduction of Atherothrombosis for Continued Health (REACH) Registry

  • T.A. Winkel

      Affiliations

    • Department of Vascular Surgery, Erasmus Medical Center, Room H 805, Erasmus MC, 's Gravendijkwal 230, 3015 GD Rotterdam, The Netherlands
    • ,
  • S.E. Hoeks

      Affiliations

    • Department of Vascular Surgery, Erasmus Medical Center, Room H 805, Erasmus MC, 's Gravendijkwal 230, 3015 GD Rotterdam, The Netherlands
    • ,
  • O. Schouten

      Affiliations

    • Department of Surgery, Reinier de Graaf Hospital, Delft, The Netherlands
    • ,
  • U. Zeymer

      Affiliations

    • Institut für Herzinfarktforschung Ludwigshafen, an der Universität Heidelberg, Ludwigshafen, Germany
    • ,
  • T. Limbourg

      Affiliations

    • Institut für Herzinfarktforschung Ludwigshafen, an der Universität Heidelberg, Ludwigshafen, Germany
    • ,
  • I. Baumgartner

      Affiliations

    • Swiss Cardiovascular Centre, Division of Clinical and Interventional Angiology, Inselspital, University Hospital, Berne, Switzerland
    • ,
  • D.L. Bhatt

      Affiliations

    • VA Boston Healthcare System and Brigham and Women's Hospital, Boston, MA, USA
    • ,
  • Ph.G. Steg

      Affiliations

    • INSERM U-698, Université Paris 7, AP-HP, Centre Hospitalier Bichat-Claude Bernard, Paris, France
    • ,
  • S. Goto

      Affiliations

    • Tokai University School of Medicine, Isehara, Kanagawa, Japan
    • ,
  • J. Röther

      Affiliations

    • Johannes Wesling Klinikum Minden, Hannover Medical School, Hannover, Germany
    • ,
  • P.P. Cacoub

      Affiliations

    • Pierre and Marie Curie University, Paris 6, AP-HP, Hospital La Pitié-Salpêtrière, Paris, France
    • ,
  • H.J.M. Verhagen

      Affiliations

    • Department of Vascular Surgery, Erasmus Medical Center, Room H 805, Erasmus MC, 's Gravendijkwal 230, 3015 GD Rotterdam, The Netherlands
    • ,
  • J.J. Bax

      Affiliations

    • Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
    • ,
  • D. Poldermans

      Affiliations

    • Department of Vascular Surgery, Erasmus Medical Center, Room H 805, Erasmus MC, 's Gravendijkwal 230, 3015 GD Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31107034613; fax: +31107034957.
    • On behalf of the REACH Registry Investigators: a complete list of the REACH Registry Investigators appears in JAMA 2006;295:180–189.

Received 1 December 2009 ,Accepted 4 March 2010.

References 

  1. Conway DS, Lip GY. Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). Am J Cardiol. 2004;93(11):1422–1425A10
  2. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis. 2002;13(Suppl. 1):1–6
  3. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189
  4. Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156(5):855–863p. 63 e2
  5. Montalescot G. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease. Clin Cardiol. 2000;23(Suppl. 6):VI-18–VI-22
  6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–2375
  7. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854–906
  8. Lane DA, Lip GY. Quality of life in older people with atrial fibrillation. J Interv Card Electrophysiol. 2009;25(1):37–42
  9. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14(6):666–672
  10. Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau C-S, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151(4)(786):e1–10
  11. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870
  12. Frykman V, Frick M, Jensen-Urstad M, Ostergren J, Rosenqvist M. Asymptomatic versus symptomatic persistent atrial fibrillation: clinical and noninvasive characteristics. J Intern Med. 2001;250(5):390–397
  13. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30(2):192–201
  14. Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–1206
  15. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155(5):469–473
  16. Ouriel K. Peripheral arterial disease. Lancet. 2001;358(9289):1257–1264
  17. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840–844
  18. Dublin S, French B, Glazer NL, Wiggins KL, Lumley T, Psaty BM, et al. Risk of new-onset atrial fibrillation in relation to body mass index. Arch Intern Med. 2006;166(21):2322–2328
  19. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005;118(5):489–495
  20. Aberg H. Atrial fibrillation. A review of 463 cases from Philadelphia General Hospital from 1955 to 1965. Acta Med Scand. 1968;184(5):425–431
  21. Davidson E, Weinberger I, Rotenberg Z, Fuchs J, Agmon J. Atrial fibrillation. Cause and time of onset. Arch Intern Med. 1989;149(2):457–459
  22. Petersen P, Godtfredsen J. Atrial fibrillation–a review of course and prognosis. Acta Med Scand. 1984;216(1):5–9
  23. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Gronbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112(12):1736–1742
  24. Kozlowski D, Budrejko S, Lip GY, Rysz L, Mikhailidis DP, Raczak G, et al. Lone atrial fibrillation – what do we know?. Heart. 2010;96:498–503
  25. Laguna P, Martin A, Del Arco C, Millan I, Gargantilla P. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice. Acad Emerg Med. 2005;12(9):828–834
  26. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Bourassa MG, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667–2677
  27. Holmes DR, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54(2):95–109
  28. Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, Budaj A, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–227
  29. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J. 2006;151(1):1–9
  30. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999–1002
  31. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151
  32. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654

PII: S1078-5884(10)00152-8

doi: 10.1016/j.ejvs.2010.03.003

European Journal of Vascular & Endovascular Surgery
Volume 40, Issue 1 , Pages 9-16 , July 2010

Article Tools

* Image Usage & Resolution